NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease

NuSirt Biopharma, a company dedicated to improving the lives of those with chronic metabolic diseases, is planning to launch a clinical trial to determine if its patented technology has potential to become a new treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). (Read More)